Foster & Motley Inc. Increases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Foster & Motley Inc. grew its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 118.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,280 shares of the biopharmaceutical company’s stock after buying an additional 12,630 shares during the quarter. Foster & Motley Inc.’s holdings in Halozyme Therapeutics were worth $1,113,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in HALO. Congress Asset Management Co. increased its position in shares of Halozyme Therapeutics by 446.5% in the third quarter. Congress Asset Management Co. now owns 2,433,579 shares of the biopharmaceutical company’s stock valued at $139,298,000 after buying an additional 1,988,238 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Halozyme Therapeutics by 76.9% during the third quarter. Handelsbanken Fonder AB now owns 1,969,169 shares of the biopharmaceutical company’s stock valued at $112,715,000 after acquiring an additional 856,200 shares during the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Halozyme Therapeutics by 698.8% during the fourth quarter. Janney Montgomery Scott LLC now owns 287,731 shares of the biopharmaceutical company’s stock valued at $13,756,000 after acquiring an additional 251,711 shares during the last quarter. Boston Trust Walden Corp boosted its stake in shares of Halozyme Therapeutics by 54.0% during the third quarter. Boston Trust Walden Corp now owns 682,616 shares of the biopharmaceutical company’s stock valued at $39,073,000 after acquiring an additional 239,321 shares during the last quarter. Finally, South Street Advisors LLC acquired a new stake in shares of Halozyme Therapeutics during the third quarter valued at $9,812,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Performance

NASDAQ HALO opened at $56.42 on Friday. The firm has a market capitalization of $7.18 billion, a P/E ratio of 18.68, a P/E/G ratio of 0.42 and a beta of 1.24. Halozyme Therapeutics, Inc. has a 1-year low of $33.15 and a 1-year high of $65.53. The company has a debt-to-equity ratio of 3.32, a current ratio of 10.36 and a quick ratio of 9.15. The business’s 50-day simple moving average is $50.50 and its 200-day simple moving average is $54.30.

Insider Activity

In related news, Director Jeffrey William Henderson sold 10,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares in the company, valued at approximately $2,180,986.11. This trade represents a 18.65 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 2.40% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on HALO. JMP Securities increased their price objective on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. HC Wainwright increased their price objective on Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Piper Sandler increased their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a “neutral” rating in a research note on Friday, January 10th. Finally, Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Four investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.